ClinicalTrials.gg
RecruitingNCT07601464TERMOMIRNAUpdated May 22, 2026

Evaluation of Tissue and Circulating microRNA Profiles in Patients With Hepatocellular Carcinoma Subjected to Thermal Ablation

An observational study in Hepatocarcinoma, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Carcinoma, Hepatocellular by IRCCS Azienda Ospedaliero-Universitaria di Bologna — 9 open to participants now, 9 under way, none of them phase 3. Carcinoma, Hepatocellular · IRCCS Azienda Ospedaliero-Universitaria di Bologna.

Planned enrollment
8th of 11
150 · median 270
Started
2026
the only one that year
Observational
11 of 13
9 open now
Registered
13th of 13
by date

Among the 13 studies in Carcinoma, Hepatocellular by IRCCS Azienda Ospedaliero-Universitaria di Bologna, this one is the 8th largest by planned enrollment of the 11 observational ones that give a count, is the only one that started in 2026, is one of 11 observational ones, and was the 13th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

9 of the 13 studies in Carcinoma, Hepatocellular by IRCCS Azienda Ospedaliero-Universitaria di Bologna are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Carcinoma, Hepatocellular by IRCCS Azienda Ospedaliero-Universitaria di Bologna, or all of them as a file.
02

Study summary

The main objectives of this research project concern the identification of microRNAs circulating and of serum metabolites predictive of treatment response in patients with early stage hepatocellular carcinoma undergoing locoregional treatment with thermoablation.

In addition, the molecular mechanisms involved in reprogramming will be identified metabolic via bioinformatics analysis and pretreatment liver biopsy analysis and analysis of screening on patient-derived primary lines for personalized therapy.

03

Conditions studied

  • Hepatocarcinoma

Keywords

  • hepatocarcinoma
  • liver cancer
  • microRNA
  • thermoablation
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients diagnosed with HCC and indicated for thermoablation for liver lesions size ≤5 cm.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18
  • Diagnosis of hepatocarcinoma confirmed by radiology (LIRADS criteria/triphasic diagnostics) or by .
  • Indication for thermoablation treatment (for radiofrequency) based on the judgment of the hepatologist/surgeon.
  • signed by the patient.

Exclusion criteria

Exclusion Criteria:

  • Presence of liver lesions of other origins.
  • History of liver transplant.
  • Severe, uncorrectable coagulopathy, contraindicating liver (where necessary) or ablative procedure.
  • Patient refusal to participate in the study or inability to obtain .
  • Pregnant women.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. circulant microRNA

    micro-RNAs differentially expressed between the complete response and disease residue groups

    Time frame: At baseline, at 24 hours, 1 month, 3 months

  2. tissue microRNA

    micro-RNAs differentially expressed between the complete response and disease residue groups

    Time frame: At baseline

  3. Metabolomic analysis

    Identification of circulating metabolites differentially expressed between the complete response and disease residue groups

    Time frame: At baseline, 24 hours, 1 month, 3 months

Secondary outcomes

  1. Relapse Free Survival

    0-1

    Time frame: 24 hours, 1 month, 3 months

  2. Overall Survival

    0-1

    Time frame: 24 hours, 1 month, 3 months

  3. Hepatocarcinoma recurrence

    Ecography

    Time frame: 24 hours, 1 month, 3 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2028, 33 months after the start.

Of 303 non-industry observational studies under Carcinoma, Hepatocellular, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 114. This study's planned 33 months is below that.

Counting every sponsor, half of 352 studies reached it within 51 months; a quarter within 32 and three quarters within 108.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2026
First posted
May 22, 2026
StartActual
Mar 26, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07601464
Responsible party
Sponsor
First posted
May 22, 2026
Start date
Mar 26, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
May 22, 2026

Study contacts

Andrea Boccatonda, MD
Contact
andrea.boccatonda@aosp.bo.it
+39 0512143265

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion